ArticleExperimental and therapeutic medicine2026
α-tocopherol in the prevention of ischemic or hemorrhagic stroke: A meta-analysis.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke remains a leading cause of disability and mortality worldwide, and the preventive role of antioxidants is of great clinical interest. The present study aimed to clarify the relationship between circulating α-tocopherol and stroke by performing a meta-analysis of prospective studies. The Web of Knowledge, Embase, Scopus, Cochrane Library and PubMed databases were searched through January 2026 for relevant studies. Risk ratios (RRs) and the corresponding 95% confidence intervals (CIs) were extracted to estimate the association of circulating α-tocopherol with stroke risk. In total, six cohort studies involving 104,209 participants and 2,194 events were identified. The results indicated that a high circulating α-tocopherol level was associated with a 22% lower stroke risk (RR, 0.78; 95% CI, 0.70-0.87). Additionally, a higher circulating α-tocopherol level was associated with a reduced stroke risk in the ischemic stroke (RR, 0.80; 95% CI, 0.72-0.90), body mass index >25 (RR, 0.80; 95% CI, 0.72-0.89), physical activity adjusted (RR, 0.69; 95% CI, 0.57-0.84) and physical activity not adjusted (RR, 0.83; 95% CI, 0.73-0.94) subgroups, but not for the hemorrhagic stroke (RR, 0.65; 95% CI, 0.41-1.01) subgroup. Dose-response analysis indicated that each 5 mg/l increment in circulating α-tocopherol was associated with an average 8% lower stroke risk (RR, 0.92; 95% CI, 0.85-0.98). In conclusion, the findings of the present meta-analysis indicates that an increased circulating α-tocopherol level may be related to lower ischemic but not hemorrhagic stroke risk. Notably, while physical activity is a critical determinant of stroke risk, the protective association of α-tocopherol remains significant and is further strengthened after accounting for this factor. This suggests that α-tocopherol may play a vital role in stroke prevention, particularly within the context of active lifestyle management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.